Efficacy and Safety of Denileukin Diftitox-Cxdl, an Improved Purity Formulation of Denileukin Diftitox, in Patients With Relapsed or Refractory Cutaneous T-Cell Lymphoma
Francine M. Foss(Yale Cancer Center), Madeleine Duvic(Cancer Clinic), Timothy M. Kuzel(Rush University), Tatyana Feldman(Hackensack University Medical Center), Chean Eng Ooi(Eisai (United States)), Pamela B. Allen(Emory University), Christiane Querfeld(City of Hope), H. Miles Prince(Peter MacCallum Cancer Centre), Henry K. Wong(Peter MacCallum Cancer Centre), Fernando Cabanillas(University of Puerto Rico, Medical Sciences Campus), Lubomir Sokol(Moffitt Cancer Center), Costas K. Yannakou(Epworth Hospital), Oleg E. Akilov(University of Pittsburgh Medical Center), Lucia Seminario‐Vidal(Eli Lilly (United States)), David C. Fisher(Dana-Farber Cancer Institute), Youn H. Kim(Stanford University), Nam H. Dang(University of Florida), Myron S. Czuczman(Roswell Park Comprehensive Cancer Center), Dongyuan Xing, Larisa J. Geskin(Columbia University Irving Medical Center), Preeti Singh(Indian Agricultural Statistics Research Institute), Nicholas Sauter(Eisai (United States))
Cited by 22
Related Papers
Randomized Controlled Trial of Yttrium-90–Labeled Ibritumomab Tiuxetan Radioimmunotherapy Versus Rituximab Immunotherapy for Patients With Relapsed or Refractory Low-Grade, Follicular, or Transformed B-Cell Non-Hodgkin’s Lymphoma
|Journal of Clinical Oncology|2002|1.2k
Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity
|The Lancet Oncology|2010|852
Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial
|The Lancet|2018|733
Clinical End Points and Response Criteria in Mycosis Fungoides and Sézary Syndrome: A Consensus Statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer
|Journal of Clinical Oncology|2011|657